Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

For the 15.5 million U.S. adults on GLP-1 medications like Ozempic and Wegovy, holiday meals can pose a challenge. Melanie ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

Biotech leader says additional research into existing medications, drug classes, and mechanisms of action can bring forth ...

The childhood obesity epidemic in GCC countries has triggered a debate on the potential use of weight-loss medications such ...

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Now, research from Henry Ford Health, has found that weight-loss drugs, including GLP-1, could also impact alcohol ...

A bipartisan group of senators are filing a bill that would force health insurers or PBMs to divest their pharmacy businesses ...

Doctors might be slow to admit it, but Ozempic and other GLP-1 drugs are making dieting and exercise obsolete.